Elysium has developed two lines of actions in NUTRACEUTICS and in ANTI-CANCER research:
NUTRACEUTICS:
o A nasal spray to fight COVID19
ELYSIUM Cell Bio ITA has developed a solution made by food additives (Polyphopshates - E452(i) Sodium polyphosphate) harmless to human body with antiviral properties. The mechanisms of action is based on: (i) human ACE2 receptor downregulation, (ii) viral RNA-dependend-RNA polymerase RdRp inibition, (iii) virus-host interaction displacement (by interaction with viral Spike protein).
Reference related to this issue:
1- https://pubmed.ncbi.nlm.nih.gov/34230209/
Italian Patent: n. 102023000016338, Aug 1 2023; n. 102024000005170, Mar 7 2024
ANTI-VIRAL DRUGS:
N.2 Small molecules have been identified:
1- PI-7 An anti-PMCA1-ATP2B1 dealing with Ca++ homeostasis in cells infected by SARS-CoV-2.
Reference: https://www.medrxiv.org/content/10.1101/2022.09.02.22279542v1
KoreanPatent: PDPB204106; PDPB204055
2- ELYSIVIR against the PI3K/Akt and TGF beta signaling cascade during SARS-CoV-2 viral infection.
Italian Patent: n. 102023000022647; Oct 27 2023.
o Three small molecules developed to fight metastatic cancer by takle tumour microenvironment , cellular T-metabolism and immune-systems.
References related to this issue:
1- https://pubmed.ncbi.nlm.nih.gov/38612726/